Welcome to the AxBlog. sign up for updates Bithia Anderson 10/5/22 Bithia Anderson 10/5/22 December 2021 New Drug Approvals Read More Bithia Anderson 12/31/21 Bithia Anderson 12/31/21 Aduhelm (aducanumab) faced another rejection from Japanese regulators after EU refusal Read More Bithia Anderson 12/31/21 Bithia Anderson 12/31/21 October 2021 New Drug Approvals Read More Bithia Anderson 11/30/21 Bithia Anderson 11/30/21 A Closer Look into Cell and Gene Therapies Read More Bithia Anderson 11/30/21 Bithia Anderson 11/30/21 November 2021 New Drug Approvals Read More Bithia Anderson 11/30/21 Bithia Anderson 11/30/21 Unlocking the Opportunities of Cell and Gene Therapies Read More Bithia Anderson 10/30/21 Bithia Anderson 10/30/21 September 2021 New Drug Approvals Read More Bithia Anderson 10/30/21 Bithia Anderson 10/30/21 Gantenerumab from Roche Receives Breakthrough Therapy Designation for Alzheimer’s Read More Bithia Anderson 10/30/21 Bithia Anderson 10/30/21 Highlights from IQVIA Report on Drug Expenditure Dynamics 1995-2020 Read More Bithia Anderson 9/30/21 Bithia Anderson 9/30/21 August 2021 New Drug Approvals Read More Bithia Anderson 9/30/21 Bithia Anderson 9/30/21 The Age of Digital Therapeutics— Golden or Not Quite Yet? Read More Bithia Anderson 9/30/21 Bithia Anderson 9/30/21 New Therapy for Alagille Syndrome Estimated at $250,000 for an Annual Regimen Read More Bithia Anderson 8/31/21 Bithia Anderson 8/31/21 ICER Final Report on Aduhelm’s Value and Cost-Effectiveness Read More Bithia Anderson 8/31/21 Bithia Anderson 8/31/21 Value-Based Contracting—Is It the Future of Reimbursement Models?(Part 2 of 2) Read More Bithia Anderson 8/31/21 Bithia Anderson 8/31/21 July 2021 New Drug Approvals Read More Bithia Anderson 7/31/21 Bithia Anderson 7/31/21 June 2021 New Drug Approvals Read More Bithia Anderson 7/31/21 Bithia Anderson 7/31/21 Gene Therapy, Libmeldy, Not Recommended by NICE Read More Bithia Anderson 7/31/21 Bithia Anderson 7/31/21 Value-based Contracting—What do Payers Need to Know?(Part 1 of 2) Read More Bithia Anderson 6/29/21 Bithia Anderson 6/29/21 FDA’s Accelerated Approval for First Alzheimer’s Drug since 2003 Read More Bithia Anderson 6/29/21 Bithia Anderson 6/29/21 May 2021 New Drug Approvals Read More Newer Posts Older Posts Start your journey with Axum
Bithia Anderson 12/31/21 Bithia Anderson 12/31/21 Aduhelm (aducanumab) faced another rejection from Japanese regulators after EU refusal Read More
Bithia Anderson 11/30/21 Bithia Anderson 11/30/21 A Closer Look into Cell and Gene Therapies Read More
Bithia Anderson 11/30/21 Bithia Anderson 11/30/21 Unlocking the Opportunities of Cell and Gene Therapies Read More
Bithia Anderson 10/30/21 Bithia Anderson 10/30/21 Gantenerumab from Roche Receives Breakthrough Therapy Designation for Alzheimer’s Read More
Bithia Anderson 10/30/21 Bithia Anderson 10/30/21 Highlights from IQVIA Report on Drug Expenditure Dynamics 1995-2020 Read More
Bithia Anderson 9/30/21 Bithia Anderson 9/30/21 The Age of Digital Therapeutics— Golden or Not Quite Yet? Read More
Bithia Anderson 9/30/21 Bithia Anderson 9/30/21 New Therapy for Alagille Syndrome Estimated at $250,000 for an Annual Regimen Read More
Bithia Anderson 8/31/21 Bithia Anderson 8/31/21 ICER Final Report on Aduhelm’s Value and Cost-Effectiveness Read More
Bithia Anderson 8/31/21 Bithia Anderson 8/31/21 Value-Based Contracting—Is It the Future of Reimbursement Models?(Part 2 of 2) Read More
Bithia Anderson 7/31/21 Bithia Anderson 7/31/21 Gene Therapy, Libmeldy, Not Recommended by NICE Read More
Bithia Anderson 7/31/21 Bithia Anderson 7/31/21 Value-based Contracting—What do Payers Need to Know?(Part 1 of 2) Read More
Bithia Anderson 6/29/21 Bithia Anderson 6/29/21 FDA’s Accelerated Approval for First Alzheimer’s Drug since 2003 Read More
